Drug Development in the New Era: A Global Perspective
4th International conference on phase 1 and early phase clinical trials
March 1-2, 2018 | Hyatt Regency Hong Kong, Tsim Sha Tsui, 18 Hanoi Road, Kowloon, Hong Kong
Dr. Xiuqin Wang, MD, PhD
Director of Research Operating Office, Jiangsu Academy of Clinical and Translational Research
Chief Ethics Officer and Vice-Chair of Institutional Review Board,
Jiangsu Province Hospital, Nanjing, China
Dr. Xiuqin Wang is Deputy Director of Department of Science and Technology; Director, Research Operating Office, Jiangsu Academy of Clinical and Translational Research; Chief Ethics Officer; also the Vice-Chair of Institutional Review Board, in Jiangsu Province Hospital.
Dr. Wang did much research on ethical review of clinical research and management of clinical trials, published more 20 papers and one monograph titled Operating Procedure for Institutional Review Board of Clinical Trial Institution. Dr. Wang has been a fellow at Human Subjects Committee of Harvard School of Public Health in 2005, and a fellow in Global Forum on Bioethics in Research in 2007. Dr. Wang is the Deputy Secretary General of China Drug Clinical Trial Institution Union, and the Secretary General of Research on Drug Clinical Evaluation Committee of Jiangsu Province Pharmaceutical Association; AAHRPP Site Visitor, FERCAP surveyor.
Day Two: Ethics Review of a Phase 1 Clinical Research in a New Technology